Cancer Genetics Unveils IPO Plan
Cancer Genetics Inc disclosed its plans for an initial public offering of up to $50 million in shares.
However, further terms of the IPO were not disclosed.
For the nine months ended Sept. 30, Cancer Genetic posted a loss of $16.8 million, versus a loss of $7.3 million, in the year-ago. Its net revenue surged 34% to $2.1 million.
Cancer Genetics intends to apply to list its shares under the symbol CGIX on the Nasdaq Global Market.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.